Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma

Richard E. Royal, Seth M. Steinberg, Robert S Krouse, Glenroy Heywood, Donald E. White, Patrick Hwu, Franco M. Marincola, David R. Parkinson, Douglas J. Schwartzentruber, Suzanne L. Topalian, James C. Yang, Steven A. Rosenberg

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

PURPOSE: We evaluated the characteristics of patients with metastatic renal cancer or metastatic melanoma prior to and during treatment with bolus intravenous interleukin-2 to define prognostic indicators of subsequent response to therapy. PATIENTS AND METHODS: A consecutive series of 509 patients with progressive metastatic cancer were treated with intravenous interleukin-2 from September 1985 to July 1993. Pretreatment demographic characteristics, treatment history, results of laboratory tests, and metastatic sites of disease were evaluated. The amount of interleukin-2 administered, toxicity, and changes in laboratory test results were recorded for the first course of therapy. Subsequent objective response to therapy and survival were determined and used to evaluate pretreatment and treatment characteristics that acted as prognostic indicators of response. RESULTS: At the end of the study, 22.6% of patients with renal cancer and 16.3% of patients with melanoma experienced an objective response to interleukin-2 therapy. Patients with renal cancer responded more frequently if they had not previously failed other immunotherapies. Also, renal cancer patients who achieved an objective response had a more profound thrombocytopenia during the first cycle of therapy. Patients with melanoma responded more frequently to interleukin-2 therapy when metastases were confined to subcutaneous tissue. In addition, responding patients with melanoma received more interleukin-2 in their first course and exhibited a more profound lymphocytosis 7 to 11 days after initiating therapy than did nonresponders. CONCLUSIONS: Renal cancer and melanoma displayed separate prognostic indicators with respect to response from interleukin-2 therapy. Although significant correlates to response were identified, there was much variability and a reliable predictive model of response to therapy could not be formulated based on these results.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalCancer Journal from Scientific American
Volume2
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Kidney Neoplasms
Interleukin-2
Melanoma
Therapeutics
Lymphocytosis
Subcutaneous Tissue
Thrombocytopenia
Immunotherapy
History
Demography
Neoplasm Metastasis

Keywords

  • Immunotherapy
  • Interteukin-2
  • Lymphocytosis
  • Melanoma
  • Neoplasm metastasis
  • Prognosis
  • Renal cell carcinoma
  • Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Royal, R. E., Steinberg, S. M., Krouse, R. S., Heywood, G., White, D. E., Hwu, P., ... Rosenberg, S. A. (1996). Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer Journal from Scientific American, 2(2), 91-98.

Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. / Royal, Richard E.; Steinberg, Seth M.; Krouse, Robert S; Heywood, Glenroy; White, Donald E.; Hwu, Patrick; Marincola, Franco M.; Parkinson, David R.; Schwartzentruber, Douglas J.; Topalian, Suzanne L.; Yang, James C.; Rosenberg, Steven A.

In: Cancer Journal from Scientific American, Vol. 2, No. 2, 1996, p. 91-98.

Research output: Contribution to journalArticle

Royal, RE, Steinberg, SM, Krouse, RS, Heywood, G, White, DE, Hwu, P, Marincola, FM, Parkinson, DR, Schwartzentruber, DJ, Topalian, SL, Yang, JC & Rosenberg, SA 1996, 'Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma', Cancer Journal from Scientific American, vol. 2, no. 2, pp. 91-98.
Royal, Richard E. ; Steinberg, Seth M. ; Krouse, Robert S ; Heywood, Glenroy ; White, Donald E. ; Hwu, Patrick ; Marincola, Franco M. ; Parkinson, David R. ; Schwartzentruber, Douglas J. ; Topalian, Suzanne L. ; Yang, James C. ; Rosenberg, Steven A. / Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. In: Cancer Journal from Scientific American. 1996 ; Vol. 2, No. 2. pp. 91-98.
@article{07610c5aec644a0a94e61861a8dc13a9,
title = "Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma",
abstract = "PURPOSE: We evaluated the characteristics of patients with metastatic renal cancer or metastatic melanoma prior to and during treatment with bolus intravenous interleukin-2 to define prognostic indicators of subsequent response to therapy. PATIENTS AND METHODS: A consecutive series of 509 patients with progressive metastatic cancer were treated with intravenous interleukin-2 from September 1985 to July 1993. Pretreatment demographic characteristics, treatment history, results of laboratory tests, and metastatic sites of disease were evaluated. The amount of interleukin-2 administered, toxicity, and changes in laboratory test results were recorded for the first course of therapy. Subsequent objective response to therapy and survival were determined and used to evaluate pretreatment and treatment characteristics that acted as prognostic indicators of response. RESULTS: At the end of the study, 22.6{\%} of patients with renal cancer and 16.3{\%} of patients with melanoma experienced an objective response to interleukin-2 therapy. Patients with renal cancer responded more frequently if they had not previously failed other immunotherapies. Also, renal cancer patients who achieved an objective response had a more profound thrombocytopenia during the first cycle of therapy. Patients with melanoma responded more frequently to interleukin-2 therapy when metastases were confined to subcutaneous tissue. In addition, responding patients with melanoma received more interleukin-2 in their first course and exhibited a more profound lymphocytosis 7 to 11 days after initiating therapy than did nonresponders. CONCLUSIONS: Renal cancer and melanoma displayed separate prognostic indicators with respect to response from interleukin-2 therapy. Although significant correlates to response were identified, there was much variability and a reliable predictive model of response to therapy could not be formulated based on these results.",
keywords = "Immunotherapy, Interteukin-2, Lymphocytosis, Melanoma, Neoplasm metastasis, Prognosis, Renal cell carcinoma, Thrombocytopenia",
author = "Royal, {Richard E.} and Steinberg, {Seth M.} and Krouse, {Robert S} and Glenroy Heywood and White, {Donald E.} and Patrick Hwu and Marincola, {Franco M.} and Parkinson, {David R.} and Schwartzentruber, {Douglas J.} and Topalian, {Suzanne L.} and Yang, {James C.} and Rosenberg, {Steven A.}",
year = "1996",
language = "English (US)",
volume = "2",
pages = "91--98",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma

AU - Royal, Richard E.

AU - Steinberg, Seth M.

AU - Krouse, Robert S

AU - Heywood, Glenroy

AU - White, Donald E.

AU - Hwu, Patrick

AU - Marincola, Franco M.

AU - Parkinson, David R.

AU - Schwartzentruber, Douglas J.

AU - Topalian, Suzanne L.

AU - Yang, James C.

AU - Rosenberg, Steven A.

PY - 1996

Y1 - 1996

N2 - PURPOSE: We evaluated the characteristics of patients with metastatic renal cancer or metastatic melanoma prior to and during treatment with bolus intravenous interleukin-2 to define prognostic indicators of subsequent response to therapy. PATIENTS AND METHODS: A consecutive series of 509 patients with progressive metastatic cancer were treated with intravenous interleukin-2 from September 1985 to July 1993. Pretreatment demographic characteristics, treatment history, results of laboratory tests, and metastatic sites of disease were evaluated. The amount of interleukin-2 administered, toxicity, and changes in laboratory test results were recorded for the first course of therapy. Subsequent objective response to therapy and survival were determined and used to evaluate pretreatment and treatment characteristics that acted as prognostic indicators of response. RESULTS: At the end of the study, 22.6% of patients with renal cancer and 16.3% of patients with melanoma experienced an objective response to interleukin-2 therapy. Patients with renal cancer responded more frequently if they had not previously failed other immunotherapies. Also, renal cancer patients who achieved an objective response had a more profound thrombocytopenia during the first cycle of therapy. Patients with melanoma responded more frequently to interleukin-2 therapy when metastases were confined to subcutaneous tissue. In addition, responding patients with melanoma received more interleukin-2 in their first course and exhibited a more profound lymphocytosis 7 to 11 days after initiating therapy than did nonresponders. CONCLUSIONS: Renal cancer and melanoma displayed separate prognostic indicators with respect to response from interleukin-2 therapy. Although significant correlates to response were identified, there was much variability and a reliable predictive model of response to therapy could not be formulated based on these results.

AB - PURPOSE: We evaluated the characteristics of patients with metastatic renal cancer or metastatic melanoma prior to and during treatment with bolus intravenous interleukin-2 to define prognostic indicators of subsequent response to therapy. PATIENTS AND METHODS: A consecutive series of 509 patients with progressive metastatic cancer were treated with intravenous interleukin-2 from September 1985 to July 1993. Pretreatment demographic characteristics, treatment history, results of laboratory tests, and metastatic sites of disease were evaluated. The amount of interleukin-2 administered, toxicity, and changes in laboratory test results were recorded for the first course of therapy. Subsequent objective response to therapy and survival were determined and used to evaluate pretreatment and treatment characteristics that acted as prognostic indicators of response. RESULTS: At the end of the study, 22.6% of patients with renal cancer and 16.3% of patients with melanoma experienced an objective response to interleukin-2 therapy. Patients with renal cancer responded more frequently if they had not previously failed other immunotherapies. Also, renal cancer patients who achieved an objective response had a more profound thrombocytopenia during the first cycle of therapy. Patients with melanoma responded more frequently to interleukin-2 therapy when metastases were confined to subcutaneous tissue. In addition, responding patients with melanoma received more interleukin-2 in their first course and exhibited a more profound lymphocytosis 7 to 11 days after initiating therapy than did nonresponders. CONCLUSIONS: Renal cancer and melanoma displayed separate prognostic indicators with respect to response from interleukin-2 therapy. Although significant correlates to response were identified, there was much variability and a reliable predictive model of response to therapy could not be formulated based on these results.

KW - Immunotherapy

KW - Interteukin-2

KW - Lymphocytosis

KW - Melanoma

KW - Neoplasm metastasis

KW - Prognosis

KW - Renal cell carcinoma

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0002018122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002018122&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 91

EP - 98

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 2

ER -